title: Long-term pharmacological therapy of Brugada syndrome: is J-wave attenuation a marker of drug efficacy?
abstract: We herein describe two patients with Brugada syndrome in whom J-waves were successfully modified by drugs. Case 1 was a 54-year-old man who presented with repeated ventricular fibrillations (VF) and J-point elevation in the right precordial and lateral leads. After administration of cilostazol (200 mg/d), J-waves disappeared and coved-type ST-segment elevation changed to a saddleback-type for 25 months. Case 2 was a 31-year-old man who presented with a VF storm and J-point elevation in the lateral leads. After administration of quinidine (300 mg/d), J-waves and coved-type ST-segment elevation disappeared for 20 months. J-wave disappearance and coved-type ST-segment elevation were followed by VF suppression, probably due to transient outward potassium current (Ito) suppression.
authors.affiliation: Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Japan.
authors.forename: Kanae
authors.initials: K
authors.lastname: Hasegawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Ashihara
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kimura
authors.forename: Hikari
authors.initials: H
authors.lastname: Jo
authors.forename: Hideki
authors.initials: H
authors.lastname: Itoh
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Yoshifusa
authors.initials: Y
authors.lastname: Aizawa
authors.forename: Minoru
authors.initials: M
authors.lastname: Horie
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D001145:Arrhythmias, Cardiac / Q000503:physiopathology*; D053840:Brugada Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D000075224:Cardiac Conduction System Disease; D000077407:Cilostazol; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004562:Electrocardiography / Q000187:drug effects*; D005500:Follow-Up Studies; D006329:Heart Conduction System / Q000002:abnormalities* / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D058987:Phosphodiesterase 3 Inhibitors / Q000008:administration & dosage; D011802:Quinidine / Q000008:administration & dosage*; D013777:Tetrazoles / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D000889:Anti-Arrhythmia Agents; D058987:Phosphodiesterase 3 Inhibitors; D013777:Tetrazoles; D011802:Quinidine; D000077407:Cilostazol